Nona Biosciences is a Boston-based biotechnology company specializing in fully human, antibody-based therapeutic discovery and development.  Our proprietary Harbour Mice^® discovery platforms are fully human transgenic mice that produce either fully human conventional or Heavy Chain only Antibody (HCAb) formats.  Nona’s HCAbs are the first and only clinically-validated, fully human, Heavy Chain-only Antibody on the market.  Fully human antibodies from the Harbour Mice^® platforms offer multiple advantages, including reduced immunogenicity and increased efficacy, which can be further extended to other antibody-based therapeutic modalities such as multi-specifics, ADCs, CAR-based and mRNA therapeutics.

Based on the Harbour Mice^® technology and Nona's comprehensive antibody capabilities and expertise, Nona is focused on driving global inventions of transformative next-generation drugs through diversified partnership strategies that include co-discovery, asset licensing, antibody discovery, and platform licensing options. Combining Nona’s antibody discovery platforms and flexible business models, more than 70 industry and academic partners have validated Nona in over 200 projects.

We are also your trusted partner for full CMC development toward IND, and afterward from the clinic into commercial release.

For more information, follow us on LinkedIn